Zometa® contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption.
Zometa® (zoledronic acid) Injection is indicated for the treatment of hypercalcemia of malignancy.
Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established.
Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
Media Articles Related to Zometa (Zoledronic Acid)
Bone mineral density improved in frail elderly women treated with zoledronic acid
Source: Bones / Orthopedics News From Medical News Today [2015.04.14]
A single intravenous dose of the osteoporosis drug zoledronic acid improved bone mineral density in a group of frail elderly women living in nursing homes and long-term-care facilities, according...
Published Studies Related to Zometa (Zoledronic Acid)
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. 
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in
Reduction in the risk of clinical fractures after a single dose of zoledronic
Acid 5 milligrams. 
1 infusion of zoledronic acid... CONCLUSIONS: In this post hoc analysis based on postrandomization subgroups,
Clinical significance of zoledronic acid and strontium-89 in patients with
asymptomatic bone metastases from non-small-cell lung cancer. 
lung cancer (NSCLC) with asymptomatic bone metastases (BMs)... CONCLUSIONS: Treatment with ZA and/or Sr-89 significantly extended the time to
Fracture risk and zoledronic acid therapy in men with osteoporosis. 
osteoporosis... CONCLUSIONS: Zoledronic acid treatment was associated with a significantly
Superiority of denosumab to zoledronic acid for prevention of skeletal-related
events: a combined analysis of 3 pivotal, randomised, phase 3 trials. 
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with
Clinical Trials Related to Zometa (Zoledronic Acid)
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older [Active, not recruiting]
Osteoporosis prevention is important in patients with osteopenia (low bone density). This
study will test the safety and efficacy of zoledronic acid in patients diagnosed with
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer [Active, not recruiting]
The primary objective of this study is to determine whether zoledronic acid (Zometa) given
once annually increases bone mineral density in men receiving hormone therapy for prostate
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer [Recruiting]
The overall purpose of this research is to evaluate the safety and side effects of
zoledronic acid (also known as Zometa) in patients before they have surgery to remove the
ZOMETAŽ (Zoledronic Acid) for Prevention of Bone Metastases [Terminated]
To determine if therapy with ZometaŽ (zoledronic acid) 4mg will be effective in preventing
the occurrence of bone metastases in prostate cancer patients at high risk of developing
them. In addition, pain and analgesic scores and overall safety are to be evaluated
throughout the study.
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis [Active, not recruiting]
The purpose of this study is to assess the effects of zoledronic acid administered at the
same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone
mineral density (BMD) gain in the lumbar spine and total hip
Reports of Suspected Zometa (Zoledronic Acid) Side Effects
Osteonecrosis of JAW (3063),
Back Pain (1223),
Exposed Bone in JAW (1084),
Neoplasm Malignant (1029), more >>
Page last updated: 2015-04-14